ArticlemSphere2022
An Adjuvant-Based Approach Enables the Use of Dominant
Article in mSphere, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 10 citations in OpenAlex.
- Article
- Two Ume6 target gene classes in the biofilm regulatory network ofbioRxiv : the preprint server for biology · 2026Article
- Candidalysin promotes fungal-specific Th17 CD4 T cell differentiation and protective systemic immunogenicity.Mucosal immunology · 2026Article
- Article
- An emergent biofilm program from inactivation of Candida albicans master regulators Efg1 and Ndt80.PLoS pathogens · 2026Article
- Expansion and optimization of the auxin-inducible degron 2 (AID2) system inbioRxiv : the preprint server for biology · 2026Article
- Candida auris skin tropism and antifungal resistance are mediated by carbonic anhydrase Nce103.Nature microbiology · 2026Article
- Ume6 protein complexes connect morphogenesis, adherence and hypoxic genes to shape Candida albicans biofilm architecture.Nature microbiology · 2025Article
- Protein kinase A signaling regulates immune evasion by shaving and concealing fungal β-1,3-glucan.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- A Brg1-Rme1 circuit inmBio · 2024Article
- Strain variation in themSphere · 2024Article
- Article
- Article
- An expanded toolkit of drug resistance cassettes formSphere · 2023Article
- AScience (New York, N.Y.) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Candida albicans is a pathobiont fungus that can colonize multiple niches in the human body but is also a frequent cause of both mucosal and systemic disease. Despite its clinical importance, a paucity of dominant selectable markers has hindered the development of tools for genetic manipulation of the species. One factor limiting the utilization of dominant selectable markers is that C. albicans is inherently more resistant to antibiotics used for selection in other species. Here, we showed that the inclusion of suitable adjuvants can enable the use of two aminoglycoside antibiotics, hygromycin B and G418, for positive selection in C. albicans. Combining these antibiotics with an adjuvant, such as quinine or molybdate, substantially suppressed the background growth of C. albicans, thereby enabling transformants expressing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.